4James PA, Oparil S, Carter BI., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint na- tional committee (JNC8)[J]. JAMA,2014,311(5) :507-520.
5Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014)[J]. Hypertens Res,2014,37(4) :253-390.
6Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the Europe- an Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J,2013,34(28):2159- 2219.
7Fang H, Chen W, Liu X, et al. The efficacy and safety of aroti- nolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension:a one year follow-up study[J]. Clin Exp Hypertens, 2014,36 (8) : 590- 595.
8Zhou W, Hong M, Zhang K, et al. Mechanisms of improved aor- tic stiffness by arotinolol in spontaneously hypertensive rats[J]. PLoS One,2014,9(2) :e88722.
9Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension[J]. J Hypertens,2008,26(2) :351-356.
10van Zwieten PA. An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenocep- tot antagonists[J]. Drugs,1993,45(4):509-517.
